Biotech Startups

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.

5 investors

Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R. Liu's lab at the Broad Institute of MIT and Harvard. The company aims to treat a broad range of genetic diseases.

5 investors

Probius develops Quantum Electrochemical Spectroscopy (QES), a label- and reagent-free electrochemical sensing technology that detects and quantifies thousands of analytes—proteins, metabolites, and cells—from microliter-scale biological samples in about 30 minutes. The platform generates digital representations of biological specimens and cloud-based multiplex assays intended to feed AI models of biology for biomarker discovery, drug development, and bioproduction quality control.

5 investors

Prolific Machines licenses an optogenetics platform that adds light-based control to cell line development and GMP biomanufacturing, letting biopharma teams retrofit existing bioreactors and hosts to raise titers and manufacture complex molecule formats. It targets biopharmaceutical developers and manufacturers seeking higher productivity on difficult programs without re-platforming.

5 investors

Protealis breeds legume crops such as soybeans and yellow peas and develops proprietary seed coatings with nitrogen-fixing bacteria adapted to the European climate. It supplies seeds and germplasm to European farmers to increase local plant-protein production for meat and dairy alternatives.

5 investors

Proteinea uses proprietary AI models and computational tools to engineer antibodies, focusing on rational design of antibody Fc domains for improved efficacy, half-life, and targeted biodistribution. It combines AI-driven design frameworks with wet-lab validation to develop Fc-optimized antibody scaffolds for therapeutic development.

5 investors

Puna Bio develops microbial biostimulants, biofertilizers, and biofungicides for seed treatment based on extremophile bacteria collected from Argentina's Puna region, aimed at improving crop yields and regenerating degraded soils. Its products target crops such as soy, cotton, beans, wheat, and barley for the agricultural sector.

5 investors

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis. The company was formed through a merger with Homology Medicines in 2024 and is led by a team with immunology and biopharmaceutical drug development experience.

5 investors

QSM Diagnostics develops point-of-care veterinary diagnostics for the rapid identification of bacterial infections. The company, a spinout of the Goluch Research Group at Northeastern University, builds sensors and medical devices for the veterinary market.

5 investors

Qualifyze offers a centralized audit management platform for life sciences supply chains, letting quality and procurement teams plan, execute, and track supplier GxP audits globally with integrated CAPA tracking. It also provides access to a large library of ready-to-use GxP audit reports to speed up supplier qualification and compliance.

5 investors

Quant Health provides a simulation platform that models diverse, real-world patient populations and their likely responses to investigational therapies, drawing on an integrated data framework spanning biomedical, clinical, and epidemiological data. It serves drug development sponsors, supporting them from early clinical development through approval.

5 investors

Range Bio (Range Biotechnologies) develops next-generation diagnostics using translational proteomics for applications in human health. It works in high-throughput laboratory sciences.

5 investors

Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.

5 investors

Reverie Labs develops cancer treatments designed to cross the blood-brain barrier and treat tumors in the central nervous system.

5 investors

Rezo maps disease networks to find insights into disease biology for drug discovery. The company operates in the biotechnology and drug discovery space.

5 investors

5 investors

A stem cell tools and technology company providing standardized platforms to accelerate regenerative medicine development and clinical trials.

5 investors

Ruby Bio uses fermentation to produce bio-based surfactants, natural food emulsifiers, polyol sweeteners, biomonomers, and oleochemicals from sugars and up-cycled waste feedstocks. Its palm-free, petroleum-free ingredients serve as sustainable replacements for synthetic materials used in detergents, food products, polymers, packaging, adhesives, and coatings.

5 investors

Ryght builds an AI platform for clinical trial site selection and feasibility, using "AI Site Twins" — digital replicas of clinical research sites — to analyze protocols and match sponsors and CROs with high-potential research sites worldwide. It also offers a free search engine (RyghtSites.com) covering 60,000+ global research sites, along with tools for site ranking and automated feasibility outreach.

5 investors

Sano provides a platform combining genetic testing, patient recruitment, and engagement tools for precision medicine clinical trials. The platform helps research teams enroll participants and manage operations more efficiently in precision medicine studies.

5 investors

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.

5 investors

Seaport Therapeutics develops therapeutics and medicines. The company is led by a founder with extensive experience building biotech platforms and advancing novel drug development programs.

5 investors

Seaspire develops safe and sustainable suncare and skincare products using Xanthochrome®, a proprietary class of biomolecules inspired by oceanic compounds. The company targets consumers seeking sun protection without harmful toxins.

5 investors

Seneca Therapeutics develops oncolytic immunotherapy drug candidates aimed at targeted treatment of solid tumors. The company operates in the biotech and cancer therapeutics space.

5 investors